HAEMATO AG Sustainability Profile
HAEMATO AG, headquartered in Germany, is a prominent player in the pharmaceutical industry, specialising in the development and distribution of innovative therapies for patients with rare diseases and complex health conditions. Founded in 1993, the company has established a strong presence across Europe, focusing on key operational regions such as Germany and other EU countries. With a commitment to enhancing patient care, HAEMATO AG offers a diverse portfolio of products, including specialty pharmaceuticals and biosimilars, which are distinguished by their high quality and efficacy. The company has achieved significant milestones, positioning itself as a trusted partner in the healthcare sector, known for its dedication to research and development. HAEMATO AG continues to make strides in the market, contributing to advancements in treatment options and improving the lives of patients worldwide.
DitchCarbon Score
How does HAEMATO AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
HAEMATO AG's score of 22 is lower than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
HAEMATO AG's reported carbon emissions
HAEMATO AG, headquartered in Germany, currently does not report any specific carbon emissions data, as there are no available figures for kg CO2e emissions. The company has not established any documented reduction targets or commitments to climate initiatives, indicating a lack of formalised climate strategy at this time. As there are no emissions data or reduction initiatives reported, HAEMATO AG's climate commitments remain unclear. The absence of specific targets or achievements suggests that the company may need to enhance its focus on sustainability and carbon management to align with industry standards and expectations.
How Carbon Intensive is HAEMATO AG's Industry?
How Carbon Intensive is HAEMATO AG's Location?
HAEMATO AG's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
HAEMATO AG has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
